‹ ›
MYP_020679
← PREVIOUS NEXT → BACK
Basic Information
LP-70
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
not Standard
31 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
INNYTSLIEELIKKSEEQQKKNEEELKKLEX
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0257644 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 31
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 PsV
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0276074 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 31
Bio-Activity Profile
Antiviral
HIV-1 JRCSF
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0319888 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 31 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 JRCSF | TZM-bl cells
0.00003±0.00001 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0380350 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 31 is Lys-C16(palmitic acid)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 HXB2 | TZM-bl cells
0.000025±0.000003 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0401338 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 31
Bio-Activity Profile
Antiviral
HIV-1 HxB2
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
FIRST PREV 1 2
Showing 5 records on this page · Page 2 of 2